Role of posaconazole in the treatment of oropharyngeal candidiasis

Abstract

Posaconazole is the newest azole antifungal approved by the US Food and Drug Administration, and possesses a broad spectrum of activity against numerous yeasts and filamentous fungi. It is available as an oral suspension and is generally well tolerated by patients, but gastrointestinal absorption is sometimes inadequate and remains a clinical concern in treating deep-seated infections. It is used routinely and effectively for the prophylaxis of invasive fungal infections in immunosuppressed hosts and is an effective treatment of oropharyngeal candidiasis, including azole-resistant disease.

Keywords:

• posaconazole
• azole
• yeasts
• filamentous fungi

Disclosure

The authors report no conflicts of interest.